Press release
Pulmonary Drugs Market: Trends and Opportunities for the Industry by 2016 - 2024
Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/pulmonary-drugs-market.html
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during the forecast period. The report estimates that the combination drugs segment will reach a valuation of US$5,217.5 mn by the end of 2024. On the other hand, in terms of geography, Asia Pacific will emerge as the leading region in the global market due to a huge pool of unmet medical demands. By the end of 2024, the Asia Pacific pulmonary drugs market is estimated to account for a share of 23.1% in the global market.
Despite the projected decline, the demand for pulmonary drugs will continue to build as the population is reeling under the high prevalence of chronic respiratory disorders. The Forum of International Respiratory Societies (FIRS) states that the about 200 million meet their fatal end due to chronic obstructive pulmonary disease (COPD) and about 235 million due to asthma. These statistics have been the primary growth drivers for the overall pulmonary drugs market in the past few years. The rising number of smokers across the globe have also triggered the demand for pulmonary drugs as they are usually at the receiving end of respiratory disorders. The World Health Organization states that consumption of tobacco leads to six million deaths every year while 600, 000 are exposed to second-hand smoke, which is known to cause asthma. Thus the changes in lifestyle are anticipated to play a crucial role in the development of global market.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16751
The global pulmonary drugs market is also benefitting from the increasing disposable incomes and the rising awareness about treating pulmonary ailments. The increasing investments made in research and development of pulmonary drug delivery systems have also favored market growth in recent times. The growing pool of unmet demands due to population explosion in several developing countries and the entry of innovative and effective drugs in the market is also anticipated to boost the uptake of these drugs in the coming few years. Analysts anticipate that the negative growth of the global pulmonary drugs market will be attributable to the patent cliffs in the coming years that will hamper the revenues of several leading players. This issue will be further addled by the entry of generic drugs in the global market. The strict regulatory process of getting these drugs approved from various authorities is also expected to dampen the spirit of the market during the forecast period. Furthermore, the wide availability of counterfeit drugs is also acting a significant impediment to the overall market.
Purchase this Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=16751<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Drugs Market: Trends and Opportunities for the Industry by 2016 - 2024 here
News-ID: 926047 • Views: …
More Releases from Transparency Market Research
Global Opioid Induced Constipation Treatment Market Set to Reach USD 5.2 Billion …
The global opioid induced constipation (OIC) treatment market is witnessing steady and sustained growth as healthcare systems worldwide place increasing emphasis on comprehensive pain management and supportive care. Valued at US$ 2.9 billion in 2025, the market is projected to reach US$ 5.2 billion by 2036, expanding at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2036. Growth is primarily fueled by the rising prevalence of chronic…
Pneumatic Flux Chipper Market Expanding at 7.4% CAGR Through 2036 - By Product T …
The global Pneumatic Flux Chipper Market is set to witness sustained and resilient growth over the next decade, underpinned by expanding heavy manufacturing activities, rising welding and fabrication demand, and continuous investments in industrial infrastructure across emerging and developed economies. According to the latest industry analysis, the market was valued at US$ 760.5 Mn in 2025 and is projected to reach US$ 1,680.8 Mn by 2036, expanding at a compound…
AI in Automotive Market Outlook 2036: Global Industry to Surge from US$ 19.8 Bil …
The AI in automotive market is entering a phase of exponential expansion, supported by rapid digitization of vehicles, growing safety mandates, and consumer demand for intelligent mobility. The global market was valued at US$ 19.8 Bn in 2025 and is projected to reach US$ 244.4 Bn by 2036, registering a remarkable CAGR of 27% from 2026 to 2036.
This growth trajectory reflects the transition of automobiles from mechanically driven products to…
Hypodermic Needles Market to Reach US$ 7.9 Billion by 2036 on Rising Injectable …
The global hypodermic needles market was valued at approximately US$ 4.2 billion in 2025 and is projected to reach around US$ 7.9 billion by 2036, expanding at a CAGR of nearly 5.8% from 2026 to 2036, driven by the rising prevalence of diabetes, cancer, and chronic diseases, growing demand for injectable drugs and biologics, and the expansion of global vaccination and immunization programs; increasing adoption of safety-engineered and disposable needles,…
More Releases for Analysts
Best crypto presale analysts monitor Pepenode allocation patterns
Top presale analysts now lead coverage by following presale allocation patterns that reveal who holds risk and who can move a market. The Pepenode (https://pepenode.io/) presale on Cardano drew attention after laddered rounds starting near $0.0010 and advancing to about $0.0011454, with reporting from CryptoTimes24 showing more than $2.12 million raised.
Practitioners treat tokenomics, verified totals and wallet concentration as first-order inputs when ranking the best crypto presale opportunities. Pepenode's buy-and-stake…
Seizing Opportunities of the Market - Analysts' Views
Artificial intelligence and chip technology, as major global trends, have sparked a frenzy in the investment world in recent years. This wave of interest has not only attracted the attention of numerous investors but also caught the eye of astute observers who have identified a unique opportunity, presenting significant prospects for themselves and investors.
Within this opportunity, investors can choose various ways to participate. On the one hand, they can invest…
AAA supports analysts readjustment of commodities ratings
Boston, MA, USA (August 19, 2011) -- Alternative Asset Analysis has announced its support for Bank of America Merrill Lynch's readjustment of its stance on commodities, preferring to favor non-cyclical commodities, such as gold, while oil has been downgraded as an alternative asset.
Alternative Asset Analysis (AAA), a research organization that advocates alternative investments, agrees with the approach from BofA Merrill Lynch Global Commodity Research team, adding that gold is retaining…
AAA Supports Analysts' Readjustment of Commodities Ratings
Bank of America Merrill Lynch has readjusted its stance on commodities, preferring to favor non-cyclical commodities, such as gold, while oil has been downgraded as an alternative asset.
Boston, MA, August 13, 2011 -- Bank of America Merrill Lynch has readjusted its stance on commodities, preferring to favor non-cyclical commodities, such as gold, while oil has been downgraded as an alternative asset.
Alternative Asset Analysis (AAA), a research organization that advocates alternative…
New Certification for Business Analysts launched
The International Business Analysis Qualifications Board (IBAQB) has launched a new certification for Business Analysts.
The new IBAQB Certified Business Analyst certification is designed for people involved in analyzing business processes within an organization, modeling businesses and process improvement: Business Analysts, Process and Product Owners, Innovators, Product Designers, Process Optimization Professionals etc. The scheme was developed in cooperation between several international experts. The content of this scheme can therefore be seen…
Carson Witter Appoints Metal and Energy Analysts
Brendon Oliver will be joining Carson Witter as a Metals Analyst in March 2011. Brendon is joining Carson Witter from UBS in London where he was a Metals Analyst since 2007. He previously worked at Lloyds Bank for 12 years and has over 16 years experience in this industry.
Simon Bartlett will be joining Carson Witter as an Energy Analyst in April 2011. Simon is joining from the Trading…
